关于湖北华强科技股份有限公司 会计政策、会计估计变更 和 会 计 差 错 更 正 事 项 的 专 项 说 明 天职业字[2024]22723 号 您可使用手机"扫一扫"或进入"注册用于证明这审计报告是否由具有执业许可的会计师事务所出具 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（htm://42c.mot.gov.cn）"进行企 关于湖北华强科技股份有限公司 会计政策、会计估计变更和会计差错更正事项的专项说明 天职业字[2024]22723 号 湖北华强科技股份有限公司全体股东: 我们接受委托,审计了湖北华强科技股份有限公司(以下简称"华强科技"或"公司")2023 年度的财务报表,并出具了标准无保留意见的审计报告(报告编号:天职业字[2024]17881 号)。 根据上海证券交易所《关于做好 2023年年度报告工作的通知》要求,现将华强科技有关会计 政策、会计估计变更和会计差错更正事项说明如下: 一、会计政策变更 公司自 2023年1月1日采用《企业会计准则解释第16 号》(财会(2022)31 号)相关规定, 根据累积影响数调整财务报表相关项目金额。上述会计政策变更对公司财务报表无影响。 二 ...

华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 2023 年度募集资金存放与使用情况的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为湖北华强科技股份有限公司（以下简称"华强科技"或"公司"）首次公开 发行股票并在科创板上市持续督导阶段的保荐机构。根据《证券发行上市保荐业 务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》）等法律法规的规定，对华强科技 2023 年度募集资金存放与使用情况进行了审慎核查，具体情况如下： 一、募集资金的基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意湖北华强科技股份有限公司首次公 开发行股票注册的批复》（证监许可〔2021〕3368 号）同意注册，公司向社会公 开发行人民币普通股 8,620.62 万股，每股面值人民币 1 元，每股发行价为人民 币 35.09 元，募集资金总额为人民币 302,497.56 万元，扣除发行费用（不含增值 税）人民币 21,282.47 ...

Financial Performance - Total operating revenue for 2023 was corrected to ¥57,275.31 million, a decrease of 2.21% from the previous year's ¥58,567.94 million[1]. - Operating profit was revised to ¥477.45 million, reflecting a significant decline of 92.52% compared to ¥6,387.20 million in the prior year[1]. - Total profit was adjusted to ¥414.26 million, down 93.41% from ¥6,287.89 million year-over-year[1]. - Net profit attributable to shareholders was corrected to ¥792.51 million, an 88.36% decrease from ¥6,807.26 million in the previous year[1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was revised to -¥7,602.74 million, a drastic change from -¥1,292.02 million in the prior year, indicating a decline of 488.44%[1]. - Basic earnings per share remained at ¥0.02, down 90% from ¥0.20 in the previous year[1]. - Total assets at the end of the reporting period were corrected to ¥505,164.53 million, a decrease of 2.13% from ¥516,166.15 million at the beginning of the period[1]. Regulatory and Compliance Issues - The company received regulatory warnings from the Hubei Securities Regulatory Bureau and the Shanghai Stock Exchange regarding the need for corrections in previous financial reports[4]. - The company expressed sincere apologies to investors for the impact of the earnings report correction[7]. - The board will enhance supervision and training on financial accounting standards to improve the quality of financial information[8].

证券代码：688151 证券简称：华强科技 公告编号：2024-021 湖北华强科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 5 月 17 日 14 点 00 分 召开地点：中国（湖北）自贸区宜昌片区生物产业园东临路 499 号会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 17 日 至 2024 年 5 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 1 股东大会召开日期：2024年5月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） ...

Financial Performance - The company reported a total distributable profit of RMB 291,352,150.30 as of December 31, 2021[6]. - A cash dividend of RMB 3.35 per 10 shares (including tax) is proposed, amounting to a total of RMB 115,407,500.00 (including tax) based on a total share capital of 344,500,000 shares[6]. - The cash dividend represents 36.04% of the net profit attributable to shareholders of the parent company for the year[6]. - In 2021, the company's operating revenue increased by 52.64% year-on-year, reaching ¥1,274,716,156.37, primarily due to the sales growth of vaccine-related products and collective protection products[22]. - The net profit attributable to shareholders of the listed company surged by 81.15% to ¥319,190,437.72, driven by increased production and sales of pharmaceutical packaging and collective protection products[22]. - The net cash flow from operating activities rose significantly by 250.88% to ¥472,426,883.36, attributed to favorable sales collection from military and major clients[24]. - The company's total assets at the end of 2021 amounted to ¥5,291,957,302.50, reflecting a 128.98% increase compared to the previous year[22]. - The net assets attributable to shareholders of the listed company increased by 265.49% to ¥4,232,666,496.85[22]. - Basic earnings per share for 2021 were ¥1.24, representing a 69.86% increase from the previous year[23]. - The gross profit margin for the main business was 42.70%, an increase of 11.34 percentage points year-on-year[70]. - The gross profit margin for special protective products was 15.77%, a decrease of 12.52 percentage points year-on-year[70]. Research and Development - The research and development expenditure accounted for 4.62% of operating revenue, slightly down from 4.74% in 2020[23]. - The company achieved a significant increase in R&D expenses, totaling approximately ¥58.92 million, representing a year-on-year growth of 48.72%[54]. - R&D expenses accounted for 4.62% of total revenue, a slight decrease of 0.12 percentage points compared to the previous year[53]. - The company holds a total of 212 intellectual property rights, including 89 invention patents, with 18 new applications filed during the reporting period[51]. - The company has developed 14 core technologies in special protection and medical packaging, enhancing its competitive edge in the market[50]. - The company is committed to expanding its research directions and scale to maintain its technological advantage in the industry[54]. - The company is focusing on building a high-quality manufacturing innovation network to meet national emergency response needs and improve capabilities[116]. Market and Product Development - The company plans to continue expanding its market presence and enhancing product offerings in the pharmaceutical packaging and collective protection sectors[24]. - The company is positioned as a professional military enterprise in the field of special protection, with a strong emphasis on research and development of protective equipment and medical packaging[35]. - The company specializes in individual protective equipment, primarily producing breathable protective suits and masks for military use, having developed three generations of these suits[36]. - The collective protective equipment includes various components such as pre-filters and ventilation devices, directly supplied to military units[36]. - The medical packaging and medical device segment includes products like pharmaceutical butyl rubber stoppers and medical masks, with the company becoming a core supplier for COVID-19 vaccine stoppers[36]. - The company has established long-term cooperative relationships with major pharmaceutical enterprises, including China National Pharmaceutical Group and Guangzhou Pharmaceutical Group[66]. - The company is committed to improving product quality by deepening quality system management and ensuring effective operation of the quality system[119]. Operational Efficiency - The company achieved intelligent production processes for pharmaceutical butyl rubber stoppers, establishing long-term partnerships with numerous pharmaceutical enterprises[36]. - The company has completed 70% of the military's current orders for breathable gas masks and 100% for specialized gas masks, solidifying its core position in the defense industry[47]. - The company has established a structured procurement process, categorizing suppliers into five types based on importance, ensuring quality and timely delivery[39]. - Military products are produced under strict military standards with real-time supervision, while civilian products follow a market-driven production model[40]. - The company has a significant reliance on foreign suppliers for raw materials, primarily from the US, Europe, Russia, and Japan, which poses risks to production and cost control[69]. - The company has a high concentration of accounts receivable, with a balance of 605.03 million RMB, accounting for 13.45% of current assets[71]. Corporate Governance and Compliance - The company has established a governance structure with a board of 9 directors, including 3 independent directors, and has formed specialized committees to ensure effective decision-making[124]. - In 2021, the company held 3 shareholder meetings and 9 board meetings, reviewing a total of 66 proposals, ensuring compliance with legal and regulatory requirements[125]. - The company emphasizes the independence of its operations, maintaining a clear separation from its controlling shareholders in business, personnel, assets, and finances[125]. - The company has established a comprehensive information disclosure management system, ensuring transparency and equal access to information for all shareholders[191]. - The company has implemented a robust ESG strategy, integrating it into core business operations to enhance long-term sustainability[168]. - The company has not faced any administrative penalties related to environmental issues in 2021[170]. Social Responsibility - The company donated a total of 5 million yuan for poverty alleviation projects, including 500,000 yuan for targeted assistance in Yanshan, Yunnan[177]. - The company has maintained a strong focus on employee rights and welfare, continuously improving management systems related to employment and benefits[168]. - The company donated a total of 700,000 yuan in 2021 to support poverty alleviation and rural revitalization efforts, with 183,600 yuan specifically for consumption assistance[180]. Future Outlook - The company plans to expand its market presence by entering three new regions in 2022, aiming for a 20% increase in market share[130]. - The company is exploring acquisition opportunities to enhance its product portfolio, with a budget of $200 million allocated for potential mergers[136]. - The company provided guidance for 2022, expecting revenue growth to be between 10% and 12%, projecting total revenue to reach approximately 1.32 billion[140]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million earmarked for potential acquisitions in 2022[140].

重要内容提示： 每股分配比例：每 10 股派发现金红利 0.083 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 证券代码：688151 证券简称：华强科技 公告编号：2024-015 湖北华强科技股份有限公司 关于 2023 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2024 年 4 月 25 日召开第二届董事会第六次会议，以 9 票同意，0 票 反对，0 票弃权的表决结果审议通过《2023 年度利润分配方案》，并同意将该议 案提交公司 2023 年年度股东大会审议。 （二）监事会意见 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配 总额不变，相应调整每股分配比例，并将另行公告具体调整情况。 一、利润分配方案内容 经天职国际会计师事务所（特殊普通合伙）审计，截至 2023 年 12 月 31 日， 湖北华强科技股份有限公司（以下简称"公司"）期末合并报表可供分配利润为 人民币235,276,213.60元， ...

华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 2023 年度现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》和《上海证券交易所上 市公司自律监管指引第 11 号——持续督导》等有关法律法规的要求，华泰联合 证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为湖北华强 科技股份有限公司（以下简称"华强科技"或"公司"）首次公开发行股票并在 科创板上市的保荐机构，于 2024 年 4 月 8 日至 2024 年 4 月 18 日对公司 2023 年度有关情况进行了现场检查。现将本次现场检查情况报告如下： 一、本次现场检查的基本情况 华泰联合证券针对华强科技实际情况制订了 2023 年度现场检查工作计划。 为顺利实施本次现场工作，提高现场工作效率，切实履行持续督导工作，华泰联 合证券于 2024 年 4 月 8 日以书面形式将现场检查事宜通知湖北华强科技股份有 限公司，并要求公司提前准备现场检查工作所需的相关文件和资料。 2024 年 4 月 8 日至 18 日，华泰联合证券现场检查人员根据事先制订的现场 检查工作计划，采取与公司高级管理人员进行沟通和询问、查看公司生产经营场 所和募 ...

Financial Performance - The company reported a net profit attributable to shareholders of RMB 68,072,565.20 for the year 2022, with a cash dividend payout ratio of 38.31%[5]. - The company's operating revenue for 2022 was ¥585,679,394.08, a decrease of 54.05% compared to ¥1,274,716,156.37 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥68,072,565.20, down 78.67% from ¥319,190,437.72 in 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,920,211.20, a decline of 104.76% compared to ¥271,684,550.93 in 2021[21]. - The net cash flow from operating activities decreased by 138.38%, resulting in -¥181,302,862.18 for 2022[24]. - The gross profit margin for the main business was 19.84%, a decrease of 22.86 percentage points year-on-year[78]. - The revenue from military products decreased by 49.97% year-on-year due to delays in military procurement plans[80]. - The company reported a large accounts receivable balance of CNY 638.89 million, accounting for 14.71% of current assets[78]. - The company’s main business revenue for the reporting period was 534.28 million RMB, a decrease of 57.60% year-on-year[89]. - The net cash flow from investment activities decreased by 2,018.34% year-on-year, primarily due to investments in structured deposits[87]. Dividend Policy - As of December 31, 2022, the total distributable profit was RMB 254,046,178.44, with a proposed cash dividend of RMB 0.757 per share (before tax) based on a total share capital of 344,500,000 shares[5]. - The company plans to maintain the total dividend amount even if there are changes in total share capital before the dividend distribution date, adjusting the per-share distribution accordingly[5]. - The company maintains a cash dividend policy that requires at least 20% of the distributable profit to be allocated as cash dividends, barring special circumstances[180]. - The company emphasizes a stable and continuous profit distribution policy, balancing investor returns with sustainable development[179]. - The board of directors is responsible for discussing and proposing the profit distribution plan, which must be approved by the shareholders' meeting[180]. Risk Management - The company has outlined various operational risks and corresponding mitigation strategies in the report, emphasizing the importance of risk management[4]. - The company has confirmed that there are no violations of decision-making procedures regarding external guarantees, ensuring compliance with regulations[8]. - The company faced significant revenue declines due to delays in military equipment orders and a drop in demand for vaccine-related products[24]. - The company is at risk of losing its competitive edge if it fails to invest adequately in R&D or if new product development cycles are too long[75]. - The company faces risks of order delays in special protective equipment due to the postponement of the "14th Five-Year" procurement plan[72]. Research and Development - The company's R&D investment as a percentage of operating revenue increased by 6.72 percentage points to 11.34% in 2022[23]. - The total R&D investment for the year was approximately ¥66.39 million, representing a 12.68% increase from the previous year, and accounting for 11.34% of total revenue[59]. - The number of R&D personnel increased to 139, making up 19.58% of the total workforce, compared to 17.96% in the previous year[65]. - The company has developed 15 core technologies, including integrated design technology for respiratory devices and early warning models for filter canister failure[55]. - The company is actively involved in research and development for next-generation military equipment, contributing to the modernization of national defense capabilities[47]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance, indicating a standard governance structure[6]. - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal requirements and maintaining effective governance[137]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards and effective decision-making[137]. - The supervisory board has held five meetings, ensuring compliance and protecting the rights of the company and its shareholders[138]. - The company established an internal control system to enhance risk prevention and operational standards[139]. Market and Industry Trends - The special protection industry is experiencing rapid growth due to increasing defense budgets and the rising demand for advanced equipment in response to nuclear and biochemical threats[45]. - The global pharmaceutical market is expected to exceed $150 billion by 2025, driven by population growth and aging demographics[48]. - The pharmaceutical packaging industry is expected to grow due to the increasing health awareness and aging population in China, providing significant opportunities for the upstream packaging materials sector[126]. - The market for nuclear and biochemical safety equipment is projected to grow due to increased demand from emergency response organizations and policy support[123]. - The competitive landscape in the military supplies industry is intensifying as more companies enter the market following the reduction of entry barriers[124]. Strategic Initiatives - The company is focusing on digital transformation with a "1331" action plan, aiming for a systematic approach to enhance digital capabilities and support the transition to smart factories[37]. - The company is committed to building an independent innovation system and increasing R&D investment to enhance its technological capabilities[129]. - The company is actively expanding into civilian markets, including medical packaging and medical devices, leveraging its technological advantages[68]. - The company plans to enhance its supply chain efficiency, aiming for a 15% reduction in operational costs by the next fiscal year[152]. - The company is committed to enhancing investor communication through various channels, including performance briefings and interactive platforms[139].

湖北华强科技股份有限公司 2023 年 度 涉 及 财 务 公 司 关 联 交 易 的 存 款 、 贷款等金融业务的专项说明 天职业字[2024]30594 号 ll 录 涉 及 财 务 公 司 关 联 交 易 的 存 款 、 贷 款 等 金 融 业 务 的 专 项 说 明 --- 1 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://zq.cnof.cov.cn）"进行主 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://zq.nof.gov.cn）"进行进行 关于湖北华强科技股份有限公司 2023 年度涉及财务公司关联交易的存款、贷款等金融业务的专项说明 天职业字[2024]30594 号 湖北华强科技股份有限公司全体股东: 我们接受委托,审计了湖北华强科技股份有限公司及其子公司(以下简称"华强科技"或 "公司")2023年12月31日的合并及母公司资产负债表、2023年度的合并及母公司利润表、 合并及母公司股东权益变动表、合并及母公司现金流量表和财务报表附注(以下简称"财务报 表"),并于 2024年4月25 日出具了"天职业字[2024]17881 号"的标 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥121,337,392.45, a decrease of 36.75% compared to the same period last year[3] - The net profit attributable to shareholders was ¥14,146,460.31, down 17.38% year-on-year[3] - The net profit after deducting non-recurring gains and losses was -¥7,531,027.53, reflecting a significant decline of 198.33%[3] - The net cash flow from operating activities was -¥85,487,838.04, a decrease of 4.32% compared to the previous year[3] - Total operating revenue for Q1 2024 was CNY 121,337,392.45, a decrease of 36.7% compared to CNY 191,850,331.44 in Q1 2023[17] - Net profit for Q1 2024 was CNY 14,146,460.31, a decline of 17.3% from CNY 17,123,244.96 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.04, down from CNY 0.05 in Q1 2023[19] Cash Flow and Liquidity - The net cash flow from operating activities was -$85,487,838.04, compared to -$81,949,557.53 in the previous year, indicating a decline in operational cash flow[22] - The net increase in cash and cash equivalents was -$1,466,870,500.46, compared to -$1,155,142,168.75 in the previous year, reflecting a significant decrease in liquidity[23] - The ending balance of cash and cash equivalents was $258,634,672.00, down from $1,390,354,676.23 in the previous year[23] - Cash received from operating activities totaled $138,056,599.35, while cash paid for operating activities was $223,544,437.39, leading to a negative cash flow from operations[22] - The company reported cash received from tax refunds amounting to $4,877,257.86, which is a key component of operational cash inflow[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,990,670,797.13, a decrease of 1.21% from the previous year-end[4] - The total current assets as of March 31, 2024, amount to ¥3,631,738,369.33, a decrease from ¥3,807,389,370.64 as of December 31, 2023, representing a decline of approximately 4.6%[12] - The cash and cash equivalents decreased to ¥953,118,858.26 from ¥2,408,551,560.14, indicating a significant reduction of about 60.4%[12] - Total liabilities as of Q1 2024 amounted to CNY 806,540,149.95, down from CNY 881,385,462.89 in the previous period[15] - The total assets as of March 31, 2024, are ¥4,990,670,797.13, down from ¥5,051,645,259.93, reflecting a decrease of approximately 1.2%[13] Research and Development - R&D investment totaled ¥14,368,760.86, representing 11.84% of operating revenue, an increase of 4.95 percentage points[4] - Research and development expenses for Q1 2024 were CNY 14,368,760.86, slightly up from CNY 13,226,047.55 in Q1 2023[17] Market and Strategic Developments - The company experienced a significant decline in medical device sales due to the recovery from public health events, impacting revenue recognition[6] - The company has not reported any new product developments or technological advancements in the current quarter[11] - There are no significant market expansion or acquisition strategies mentioned in the current report[11] - The company has not provided any forward-looking guidance or performance outlook for the upcoming quarters[11] Shareholder Information - The top two shareholders are China Ordnance Equipment Group with 45.52% and Southern Industrial Asset Management with 24.83% of shares[8] Non-Recurring Gains - Non-recurring gains totaled ¥21,677,487.84, influenced by a 129.04% increase in fair value changes of structured deposits[6]